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BACKGROUND: Many women with early-stage breast cancer are working at the time of diagnosis and survive without disease recur-
rence. The short-term impact of chemotherapy receipt on employment has been demonstrated, but the long-term impact merits fur-
ther research. METHODS: The authors conducted a longitudinal multicenter cohort study of women diagnosed with nonmetastatic
breast cancer between 2005 and 2007, as reported to the population-based Los Angeles and Detroit Surveillance, Epidemiology, and
End Results program registries. Of 3133 individuals who were sent surveys, 2290 (73%) completed a baseline survey soon after diag-
nosis and of these, 1536 (67%) completed a 4-year follow-up questionnaire. RESULTS: Of the 1026 patients aged<65 years at the
time of diagnosis whose breast cancer did not recur and who responded to both surveys, 746 (76%) worked for pay before diagnosis.
Of these, 236 (30%) were no longer working at the time of the follow-up survey. Women who received chemotherapy as part of their
initial treatment were less likely to be working at the time of the follow-up survey (38% vs 27%; P5.003). Chemotherapy receipt at
the time of diagnosis (odds ratio, 1.4; P5 .04) was found to be independently associated with unemployment during survivorship in a
multivariable model. Many women who were not employed during the survivorship period wanted to work: 50% reported that it was
important for them to work and 31% were actively seeking work. CONCLUSIONS: Unemployment among survivors of breast cancer 4
years after diagnosis is often undesired and appears to be related to the receipt of chemotherapy during initial treatment. These find-
ings should be considered when patients decide whether to receive adjuvant chemotherapy, particularly when the expected benefit
is low. Cancer 2014;120:1854–62. VC 2014 American Cancer Society.
KEYWORDS: employment, breast cancer, chemotherapy, survivorship, work, survey, Surveillance, Epidemiology, and End Results
(SEER).
INTRODUCTION
Greater than 225,000 women are diagnosed with invasive breast cancer in the United States each year,1 the majority of
whom are of working age and survive through the typical age for retirement. Some work loss during the treatment period is
common as patients balance an arduous treatment schedule and acute side effects with work and family life. However, less is
known regarding the long-term impact of cancer treatments on paid employment. Because workmay be intrinsically reward-
ing and is also an important source of income, insurance, and social interactions, loss of work may profoundly affect quality
of life in addition to causing economic losses for society, particularly when it extends beyond the treatment period. There-
fore, understanding the long-term effects of treatment on employment status is a critical focus of survivorship research.2
Previous studies have primarily evaluated the employment trajectory of patients with breast cancer during treatment
and soon thereafter. In a population-based study of US patients 9 months after a diagnosis of breast cancer, we previously
reported that 24% had missed> 1 month of work and 32% had stopped working altogether due to breast cancer or its
treatment.3 Similarly, a Dutch study found that only 70% of workers with breast cancer had even partially returned to
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work 1 year after their breast cancer diagnosis.4 Other
studies have suggested that women do eventually return to
work. In a longitudinal US study conducted from 2001
through 2002, only 17% of previously employed breast
cancer survivors were not working at 18 months.5,6 In a
population-based study of Swedish patients with breast
cancer, only 11% of those who worked before diagnosis
were not working 16 months later.7 Thus, existing data
suggest substantial effects of cancer diagnosis and treat-
ment on employment during the first year after diagnosis
but a possible waning of impact by the second year.
Less is known concerning the long-term employ-
ment outcomes of survivors of breast cancer, and specifi-
cally whether certain subgroups of patients with cancer
are particularly vulnerable to loss of desired employment
during the long-term survivorship period.8 Previous
research has suggested that long-term survivors of breast
cancer are, in general, less likely to be employed than their
counterparts without breast cancer.9,10 Cancer survivors
may experience a change in their desire for work, prioritiz-
ing volunteerism, family, or leisure more after facing a
life-threatening illness.11 Survivors might also face dis-
crimination from employers.12-14 Long-term morbidity
related to either treatment or disease recurrence may
reduce survivors’ ability to work.15-19 Moreover, treat-
ments may have led to periods of missed work that may
have lasting consequences on survivors’ subsequent ability
to maintain long-term employment.
The potential impact of chemotherapy on long-term
employment outcomes in particular requires further
investigation. We previously found that patients who
received chemotherapy were more likely to stop working
in the short term,3 and in a sample of low-income survi-
vors of breast cancer, others have found that very poor
women who stop working during chemotherapy are at
risk of not returning to work in the longer term.20 Yet
others have found no effect of chemotherapy on return to
work.6,21 Moreover, relatively little is known regarding
whether those who fail to return to work are actively seek-
ing work.
Experts in the field have identified desirable meth-
odologic criteria for studies of work after cancer,22 includ-
ing population-based sampling, longitudinal design,
detailed measures, and adequate sample size. We devel-
oped a study that fulfilled these criteria and conducted a
longitudinal study inquiring about work outcomes in the
population-based sample of patients with breast cancer we
had previously surveyed near the time of diagnosis,3 seek-
ing specifically to investigate whether chemotherapy
receipt as part of the initial treatment was associated with
the employment outcomes among long-term survivors of
breast cancer.
MATERIALS AND METHODS
Study Sample
We conducted a longitudinal, multicenter cohort study of
women diagnosed with breast cancer in metropolitan Los
Angeles and Detroit. A major prespecified objective of the
current study was to examine racial/ethnic differences in
disruption of paid work for patients with breast cancer
into the survivorship period. Patients aged 20 years to 79
years and diagnosed with American Joint Committee on
Cancer (AJCC) stage 0 to III breast cancer between June
2005 and February 2007, as reported to the National
Cancer Institute’s Surveillance, Epidemiology, and End
Results (SEER) population-based program registries in
those regions, were eligible for sample selection. Using a
population-based registry allows for a study sample that is
generally representative of the population of incident can-
cer cases in the respective geographic area in terms of sex,
race or ethnicity, age, and other demographic characteris-
tics. We used the rapid case ascertainment method, which
allows the SEER registries to identify patients within 1
month of their diagnosis.23
Patients were excluded if they had stage IV breast
cancer or could not complete a questionnaire in English
or Spanish. Asian women in Los Angeles were excluded
because of enrollment in other studies (the Los Angeles
SEER protocol limits patient enrollment into multiple
concurrent studies). Latina (in Los Angeles) and black (in
both Los Angeles and Detroit) patients were oversampled
to ensure sufficient minority representation.
Questionnaire Design and Content
We developed original questionnaires after considering
the existing literature, measures previously developed to
assess relevant constructs,3,24 and theoretical models.
Measures in the survey were pretested to maximize reli-
ability and validity and were based on a priori hypotheses
generated from preliminary studies, which suggested gaps
in return to paid work after treatment of breast cancer.
Survey content included extensive batteries of questions
addressing paid work, financial issues, and other quality-
of-life factors. Additional content in the 38-page initial
survey questionnaire and 42-page follow-up survey ques-
tionnaire addressed other treatment and care issues rele-
vant during the survivorship period (see online
supporting information). To avoid response bias, survey
recipients received survey questionnaires simply entitled
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“A Study of Women’s Experiences with Treatment for
Breast Cancer” (see online supporting information).
Data Collection
After Institutional Review Board approval, eligible
patients were identified and informed of all aspects and
the intent of the study in the survey materials. The Institu-
tional Review Board approved a waiver of a written signa-
ture of informed consent, with the return of a completed
survey taken to indicate informed consent. After notifying
physicians, we first recruited and surveyed patients at a
mean of 9 months after diagnosis (mean time from diag-
nosis to survey response, 284 days; standard deviation, 96
days). We then contacted all respondents approximately 4
years later (mean time from diagnosis to survey response,
1524 days; standard deviation, 143 days). To encourage
responses, we provided a $10 cash incentive along with
the paper survey mailing and used a modified Dillman
method,25 including reminders to nonrespondents. All
materials were sent in English and in Spanish to those
with Spanish surnames.26 Responses to the baseline and
follow-up surveys were combined into a single data set,
into which clinical data from SEER were merged. The
evolution of the sample is detailed in Figure 1.
Measures
Our primary dependent variable for analysis was defined
by selecting those women who reported working (regard-
less of whether they were employed full time or part time)
before diagnosis (as reported in the baseline question-
naire) and then determining which of these reported in
the follow-up survey that they were not working at that
time.
We considered several independent variables. Clini-
cal factors included SEER-reported clinical stage of dis-
ease (AJCC stage 0, I, II, or III) and patient-reported
comorbidity and treatment (chemotherapy, radiotherapy,
and surgery) as measured in the baseline survey. Sociode-
mographic factors were determined in the baseline ques-
tionnaire, including age, race/ethnicity, educational
status, family income, marital status, work hours at the
time of diagnosis (full time vs less than full time), and
employment support (having a job with sick leave and/or
a flexible schedule). Geographic site (Los Angeles vs
Detroit) was also included in the analyses.
We measured in the follow-up survey patients’ per-
ceptions of whether, since the time of diagnosis, they were
worse off with regard to health insurance, employment
status, and financial status. We also evaluated, among
those women not working at the time of the follow-up
survey, how important it was for them to work and
whether they were actively seeking employment.
Statistical Analysis
To allow statistical inferences to be more representative of
the original targeted population, we applied survey
weights and implemented a multiple imputation method
to the calculation of percentages and regression analyses.27
All percentages reported below are so weighted and
reported alongside unweighted numbers. Design weights
compensated for the disproportionate selection across
race and SEER sites; survey unit nonresponse weights
compensated for the fact that women with certain charac-
teristics were not as likely to respond to the surveys
(patients who did not respond to both surveys were more
likely to be African American [35.2% vs 26.7%;
P< .001], to be Latina [17.2% vs 13.3%; P5 .002], to
have stage II-III disease [54.9% vs 37.8%; P< .001], and
to have undergone a mastectomy [37.5% vs 30.8%;
P< .001]). Among patients who responded to both sur-
veys, missing data due to survey item nonresponse consti-
tuted 10% of the analytic sample when all covariates in
the final model were considered simultaneously. To
address missing data from nonresponse to an item, we first
multiply imputed the data 5 times followed by combining
the results from statistical analyses on these 5 imputed
data sets using the Rubin’s formula.28,29 We limited our
analytic sample to patients aged <65 years at diagnosis,
whose breast cancer did not recur before the follow-up
survey, who responded to both surveys, and who reported
working for pay before their diagnosis in the baseline
Figure 1. Flow of patients into the study from those initially
identified to the final analytic sample is shown. SEER indi-
cates Surveillance, Epidemiology, and End Results.
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survey. We examined patterns and correlates of paid work
at the time of the follow-up survey using chi-square tests
for univariate analyses and logistic regression analysis for
multivariable analyses, which included the following the-
oretically selected independent variables: age, number of
comorbidities, race, education, family income, work
hours at the time of diagnosis, employment support, mar-
ital status, AJCC stage of disease, chemotherapy receipt,
surgery type, radiation receipt, and geographic site. In the
logistic regression analysis, we tested for interactions
between chemotherapy use and other covariates in the
model as well as between family income and geographic
site. These interactions were not found to be significantly
associated with work loss and we subsequently eliminated
them from the final model. Collinearity of the covariates
was assessed using variance inflation factors.30 All analyses
were conducted using SAS statistical software (version
9.2; SAS Institute Inc, Cary, NC).
RESULTS
Of the 1026 patients aged< 65 years at the time of diag-
nosis whose breast cancer did not recur and who
responded to both surveys, 746 (76%) reported working
for pay before diagnosis in the baseline survey. Of these,
236 patients (30%) were no longer working at the time of
the follow-up survey.
Table 1 describes the clinical and sociodemographic
characteristics of the sample, and Table 2 presents the
bivariate correlates of employment at the time of the
follow-up survey. As shown in Tables 1 and 2, 61% of
respondents had received chemotherapy. Women who
received chemotherapy as part of their initial cancer treat-
ment were more likely to report that they were not work-
ing at the time of the follow-up survey (38% vs 27%;
P5 .003). There was no statistically significant difference
noted by chemotherapy receipt in the percentage of
respondents who considered themselves to be retired at
the time of the follow-up survey (13% of patients receiv-
ing chemotherapy and 14% of those not receiving chemo-
therapy; P5 .48).
Figure 2 depicts the pattern of employment among
women who were employed at the time of their breast
cancer diagnosis. Women who were employed at the time
of diagnosis were substantially less likely to be employed
after their initial treatment if they had received chemo-
therapy. Long-term survivors were also less likely to be
employed 4 years after diagnosis if they had received
chemotherapy as part of their initial treatment.
The excess unemployment observed for women who
received chemotherapy began soon after diagnosis. Com-
pared with women who did not receive chemotherapy,
women who did were more likely to report stopping
work 2 years before the follow-up survey (30% vs 14%;
P< .001) and were more likely to have stopped work dur-
ing the initial course of therapy (56% vs 13%; P< .001).
Overall, 26% of patients treated with chemotherapy and
9% of others were not working both after the initial treat-
ment and in the long-term, 22% of patients treated with
chemotherapy and 7% of others were not working after
TABLE 1. Characteristics of Patient Sample
(n5746)
Characteristic No. % of Samplea
Age at diagnosis, y
<46 169 25.5
46-55 328 41.7
56 248 32.7
No. of comorbidities
0 186 26.5
1 205 26.5
2 355 47.0
Race
White 353 42.4
Black 191 17.7
Latina 185 38.0
Other 17 1.9
Education
High school 185 29.5
Some college 282 37.0
College graduate 273 33.5
Family income at time of baseline survey
<$20,000 82 21.0
$20,000-$69,999 292 39.1
$70,000 301 39.9
Work status at time of diagnosis
Employed full time 606 80.5
Employed part time or occasional 140 19.5
Employment support
Sick leave and/or flexible schedule 478 59.2
None 268 40.8
Marital status
Not married or partnered 293 39.7
Married or partnered 453 60.3
AJCC stage of disease
0 184 18.8
I 255 32.5
II 237 37.1
III 67 11.7
Chemotherapy receipt
No 338 39.4
Yes 389 60.6
Surgery type
Lumpectomy 478 60.5
Mastectomy 268 39.5
Radiation receipt
No 208 30.6
Yes 522 69.4
Geographic site
Los Angeles 417 79.5
Detroit 329 20.5
Abbreviation: AJCC, American Joint Committee on Cancer.
a Percentages are weighted and missing values have been imputed.
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their initial treatment but were working again in the long-
term, 11% of patients treated with chemotherapy and
17% of others had not stopped work after their initial
treatment but were not working in the long-term, and
41% of patients treated with chemotherapy and 67% of
others continued working both after the initial treatment
and in the long-term.
Table 3 presents a multivariable model for 4-year
unemployment. Patients who reported receiving chemo-
therapy at the time of diagnosis were significantly more
likely to report unemployment at 4 years (odds ratio
[OR], 1.42; 95% confidence interval [95% CI], 1.03-
1.98). Other significant correlates of 4-year unemploy-
ment were older age (OR, 1.42 for age 56 years com-
pared with age <46 years; 95% CI, 1.03-1.95), greater
number of comorbidities (OR, 2.16 for 2 comorbidities
vs none; 95% CI, 1.59-2.94), and lack of employment
support (OR, 1.33; 95%CI, 1.08-1.67).
Many women who were not employed in the survi-
vorship period wanted to work. Of the 127 women who
had not worked since diagnosis, 63 (55%) reported that it
was important for them to work and 39 (39%) were
actively looking for work. These figures were similar for
patients who did and did not receive chemotherapy dur-
ing the initial treatment period: 31% versus 32% were
actively looking for work (P5 .96) and 50% versus 49%
reported that work remained important to them
(P5 .76). Moreover, those who were no longer working
were significantly more likely to report that they were
worse off with regard to their insurance status and finan-
cial status, as depicted in Figure 3 (P< .001 for each).
DISCUSSION
In this longitudinal survey in 2 diverse US metropolitan
areas, approximately one-half of the women diagnosed
with early-stage breast cancer were of working age and
TABLE 2. Bivariate Analyses of 4-Year
Unemployment
Characteristic
% With 4-Year
Unemploymenta P
Age at diagnosis, y .005
<46 30.2
46-55 28.5
56 43.2
No. of comorbidities <.001
0 17.4
1 24.7
2 48.1
Race <.001
White 26.4
Black 31.0
Latina 43.0
Other 39.7
Education <.001
High school 48.6
Some college 29.8
College graduate 25.0
Family income at time of baseline survey <.001
<$20,000 52.1
$20,000-$69,999 34.7
$70,000 23.3
Work status at time of diagnosis .48
Employed full time 33.0
Employed part time or occasional 36.7
Employment support <.001
Sick leave and/or flexible schedule 24.7
None 46.8
Marital status .44
Not married or partnered 35.7
Married or partnered 32.5
AJCC stage of disease .020
0 29.4
I 26.8
II 39.6
III 41.9
Chemotherapy receipt .003
No 26.7
Yes 38.3
Surgery type .039
Lumpectomy 30.4
Mastectomy 38.8
Radiation receipt .75
No 34.6
Yes 33.4
Geographic site .59
Los Angeles 34.2
Detroit 32.0
Abbreviation: AJCC, American Joint Committee on Cancer.
a Percentages are weighted and missing values have been imputed.
Figure 2. Employment outcomes are shown as the percent-
age of women working before their diagnosis, at the time of
the baseline survey (approximately 9 months after diagnosis:
“the initial treatment period”), and at the time of the follow-
up survey (approximately 4 years later: “the survivorship
period”) by receipt of chemotherapy (Chemo).
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had paid employment at time of diagnosis. We found that
nearly one-third of those employed before diagnosis were
no longer working 4 years later, and many of these women
continued to desire employment. Patients who had
received chemotherapy as part of their initial course of
therapy were less likely to be working 4 years after diagno-
sis than patients who did not receive chemotherapy, after
controlling for other factors.
To our knowledge, published studies of cancer and
employment outcomes to date have provided limited in-
formation regarding the long-term impact of diagnosis
and treatment on survivors of breast cancer. In analyses of
the Health and Retirement Study10,11 and the National
Health Interview Survey,31 cancer survivors were found to
be less likely to work than controls without cancer. How-
ever, absent information concerning key clinical charac-
teristics such as cancer stage and treatment, the
mechanisms by which a cancer diagnosis affects long-term
employment have remained uncertain.
Understanding which subgroups of cancer patients
are most vulnerable to long-term work loss is critical for
clinicians and policymakers seeking to develop appropri-
ate interventions.32 In particular, the impact of treatments
and social supports are important considerations because
these are potentially modifiable. Previous studies have
suggested an important influence of employment sup-
port3,6,7,33 or chemotherapy receipt21,34,35 on the short-
term employment outcomes of survivors of breast cancer,
including missed work, work hours, and short-term job
loss. The results of the current study suggest that both of
these factors may also have a long-lasting negative impact
on paid employment.
We were particularly interested in chemotherapy
as a risk factor for long-term unemployment because
of the potential for the impact of long-term toxicities
such as neuropathy or neurocognitive effects, as well
as potential downstream effects of missed work during
treatment due to acute toxicity. To the best of our
TABLE 3. Multivariable Model of Long-Term Work
Loss
Characteristic OR (95% CI) P
Age at diagnosis, y .031
<46 1 (referent)
46-55 0.76 (0.57-1.01)
56 1.42 (1.03-1.95)
No. of comorbidities <.001
0 1 (referent)
1 0.84 (0.61-1.17)
2 2.16 (1.59-2.94)
Race .161
White 1 (referent)
Black 0.86 (0.53-1.38)
Latina 1.42 (0.87-2.33)
Other 0.94 (0.34-2.56)
Education .31
High school 1 (referent)
Some college 0.86 (0.65-1.15)
College graduate 0.98 (0.7-1.37)
Family income at time of baseline survey .081
<$20,000 1 (referent)
$20,000-$69,999 1.00 (0.74-1.34)
$70,000 0.73 (0.51-1.04)
Work status at time of diagnosis .89
Employed full time 1 (referent)
Employed part time or occasional 0.98 (0.75-1.28)
Employment support .011
Sick leave and/or flexible schedule 1 (referent)
None 1.33 (1.08-1.67)
Marital status .95
Not married or partnered 1 (referent)
Married or partnered 1.01 (0.63-1.61)
AJCC stage of disease .183
0 1 (referent)
I 0.81 (0.55-1.2)
II 1.04 (0.69-1.55)
III 1.01 (0.48-2.12)
Chemotherapy receipt .038
No 1 (referent)
Yes 1.42 (1.03-1.98)
Surgery type .28
Lumpectomy 1 (referent)
Mastectomy 0.82 (0.57-1.18)
Radiation receipt .56
No 1 (referent)
Yes 1.12 (0.75-1.68)
Geographic site .27
Los Angeles 1 (referent)
Detroit 1.14 (0.9-1.43)
Abbreviation: 95% CI, 95% confidence interval; AJCC, American Joint
Committee on Cancer; OR, odds ratio.
Figure 3. Perceptions of long-term survivors of breast cancer
regarding their insurance status and financial status are
shown based on their current employment status. Bars repre-
sent the percentage of survivors who reported being worse
off at the time of the follow-up survey (approximately 4
years after diagnosis).
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knowledge, few studies to date have examined the
long-term impact of chemotherapy on employment
outcomes. In a study of patients diagnosed with lym-
phoma or endometrial or prostate cancer between
1989 and 1998 in the Netherlands, chemotherapy
receipt appeared to increase the risk of work loss.36 In
contrast, researchers who interviewed patients diag-
nosed with breast cancer in Quebec in 1996 and
1997 found no association between receipt of chemo-
therapy and employment status at the time of follow-
up 3 years later.21 The contrast with the findings of
the current study may be the result of changes in
chemotherapy regimens and dose intensity by the
time of the current study or differences in social poli-
cies and employer accommodations between the 2
countries. The timing of the current study, which
spanned a period of national economic recession, may
also have accentuated the adverse impact of chemo-
therapy on employment outcomes. In a recent study
of a low-income sample of patients in the United
States, chemotherapy receipt was found to be an inde-
pendent predictor of long-term failure to return to
work, a finding that is consistent with the current
study.20
The current study has several strengths, including its
large, diverse sample; longitudinal design; and access to
both clinical data and patient reports of treatment, socioe-
conomic characteristics, and policy-relevant outcomes.
Several limitations also merit comment. First, the study
was located in 2 large metropolitan areas, which may limit
the generalizability of the findings, particularly to more
rural areas. Second, many of our measures were drawn
from patient self-report, which may have introduced bias.
However, evidence supports the validity of self-report in
this context.37 Third, although we had access to some
clinical information, we did lack information regarding
the specific chemotherapy regimens used, thereby pre-
cluding our ability to differentiate whether certain
approaches have a greater impact on employment out-
comes. We also lacked sufficient detail regarding the na-
ture of women’s jobs to include this in the analysis, nor
did we have information concerning spousal employment.
Fourth, although the response rate to our surveys was
high, it is possible that response bias may also have influ-
enced the results. However, we believe it is very unlikely
that correcting nonresponse bias would attenuate the asso-
ciation between chemotherapy and long-term employ-
ment status observed in the current study. Although we
did not have valid information regarding chemotherapy
receipt at time of sampling, patients who received chemo-
therapy may have been less likely to complete our baseline
survey because it was administered during the treatment
period. However, we do not believe that patients treated
with chemotherapy who did not respond were less vulner-
able to work loss than those who responded. In fact, the
opposite may be more plausible, to the extent that those
experiencing the greatest acute toxicity from chemother-
apy might have been less likely to complete a survey at 9
months after diagnosis and might in fact have been those
most vulnerable to employment loss related to treatment.
Thus, we may actually have underestimated the negative
impact of chemotherapy on paid work outcomes. Finally,
we also lacked information regarding the employment
outcomes of women without cancer during the time of
the current study, which spanned a major recession.
Although this information was not necessary to address
our primary research question regarding the association
between adjuvant chemotherapy and long-term employ-
ment outcomes, it might have provided potentially inter-
esting context if available. Moreover, as noted earlier,
because the recession may have accentuated any relation-
ship between chemotherapy and subsequent unemploy-
ment, the findings of this study should not be generalized
to settings in which the economic environment differs
substantially from that experienced by the survivors we
studied.
Similar to any observational study, challenges exist
in interpreting causation. However, it appears unlikely
that women with a higher risk of job loss for other reasons
would have been more likely to receive chemotherapy.
Indeed, we explored other potential explanatory or con-
founding factors for differential job loss by chemotherapy
groups and did not observe an association with chemo-
therapy receipt, including insurance status, reasons for
stopping work (eg, retirement), or less motivation to con-
tinue work (eg, less importance of work or job seeking)
into the survivorship period. It is of course possible that
an unmeasured factor might play a confounding role.
However, the most plausible candidates for unmeasured
factors associated with both chemotherapy receipt and
with work loss act in a direction to strengthen rather than
weaken the association observed. For example, one
unmeasured factor might be the geographic microenvir-
onment. Individuals who live in less populated areas
would be expected to have less access to chemotherapy
and also less access to jobs.
In conclusion, the results of the current study sug-
gest that loss of paid employment after a diagnosis of
breast cancer may be common, often undesired, not re-
stricted to the treatment period, and potentially related to
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the type of treatment administered. Many clinicians
believe that although patients may miss work during treat-
ment, they will “bounce back” in the longer term. The
results of the current study suggest otherwise and high-
light a possible adverse consequence of adjuvant chemo-
therapy. The findings reported here support current
efforts to reduce the morbidity and burden of treatments
for breast cancer.38 Indeed, such initiatives are actively
being evaluated, including better strategies to identify
those patients who might omit adjuvant chemotherapy
because the marginal benefit is small.39-41 The results of
the current study reinforce the need to advance these eval-
uative strategies to help physicians “first, do no harm.”
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